Digital pathology lab deploys ‘world’s 1st’ AI-powered solution for gastrointestinal cancers
Tel Aviv, Israel-based Ibex Medical Analytics has launched what it says is the world’s first artificial intelligence-powered pathology solution for diagnosing gastrointestinal cancer.
Maccabi Healthcare Services, one of the country’s top Health Maintenence Organizations, and its KSM Research and Innovation Center teamed up to deploy Galen Gastric at Maccabi's pathology institute, the organizations announced Tuesday. The tool uses AI and machine learning to help pathologists with quality control, reduce turnaround times and detect gastric cancer, dysplasia, H. pylori and other relevant findings.
“The clinical benefits from using Ibex’s AI solutions have been the key driver in Maccabi’s decision to fully adopt digital pathology, and we are impressed by how fast AI technology has become an indispensable part of our diagnostic pathway,” Judith Sandbank, MD, director of the Pathology Institute at Maccabi Healthcare Services, said Aug. 24. “We look forward to benefiting from its new insights in everyday practice.”
The platform, which also assesses breast and prostate biopsies, performed well during clinical testing, according to results published in The Lancet Digital Health. And this past June, the U.S. Food and Drug Administration granted the tool Breakthrough Device Designation.
"The Galen platform … lays the foundation to clinical-grade computational solutions that accurately identify dozens of features and become the physician’s perfect companion, helping provide every patient with an accurate, timely and personalized cancer diagnosis,” Chaim Linhart, co-founder and CTO of Ibex, added in a statement.
Matt joined Chicago’s TriMed team in 2018 covering all areas of health imaging after two years reporting on the hospital field. He holds a bachelor’s in English from UIC, and enjoys a good cup of coffee and an interesting documentary.